FAQ on Soligenix Inc.'s HyBryte(TM) and Its Impact on Cutaneous T-Cell Lymphoma Treatment
Summary
What is HyBryte(TM) and what does it treat?
HyBryte(TM) is Soligenix Inc.’s proprietary photodynamic therapy developed to treat early-stage cutaneous T-cell lymphoma (CTCL), a rare form of cancer affecting the skin, with promising efficacy shown in clinical trials.
How effective is HyBryte(TM) according to the latest trial results?
The latest clinical trial results show that 75% of patients achieved ‘Treatment Success’ after 18 weeks of HyBryte(TM) treatment, indicating its potential as a safe and fast-acting therapy for CTCL.
What is Soligenix Inc.’s focus in the biopharmaceutical industry?
Soligenix Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies for rare and difficult-to-treat diseases, including CTCL, with a pipeline that also addresses psoriasis, inflammatory diseases, and vaccine development for diseases like COVID-19.
What are the next steps for HyBryte(TM) following the successful Phase 3 study?
Following the successful completion of the second Phase 3 study, Soligenix Inc. will seek regulatory approvals to support the potential commercialization of HyBryte(TM) worldwide for the treatment of CTCL.
Where can I find more information about Soligenix Inc. and its research?
More information about Soligenix Inc. and its research can be found on the company’s website at www.Soligenix.com or in the company’s newsroom at https://ibn.fm/SNGX.
What other diseases is Soligenix Inc. targeting with its research?
Beyond CTCL, Soligenix Inc. is targeting psoriasis with SGX302, inflammatory diseases including oral mucositis in head and neck cancer with dusquetide (SGX942), Behçet’s disease with SGX945, and developing vaccines for ricin toxin, filoviruses like Marburg and Ebola, and COVID-19 with CiVax(TM).
How is Soligenix Inc.’s vaccine development supported?
Soligenix Inc.’s vaccine development, including for COVID-19, ricin toxin, and filoviruses, is supported by government grants and contract funding from NIAID, DTRA, and BARDA, utilizing its proprietary ThermoVax(R) heat stabilization platform technology.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 112115